Market News

$-0.43 EPS Expected for Minerva Neurosciences, Inc. (NERV); Cognios Capital Decreased Its Public Storage (PSA) Position

Cognios Capital Llc decreased Public Storage (PSA) stake by 12.8% reported in 2017Q3 SEC filing. Cognios Capital Llc sold 1,420 shares as Public Storage (PSA)’s stock declined 5.00%. The Cognios Capital Llc holds 9,671 shares with $2.07 million value, down from 11,091 last quarter. Public Storage now has $33.20B valuation. The stock increased 2.38% or $4.44 during the last trading session, reaching $190.75. About 2.53 million shares traded or 160.82% up from the average. Public Storage (NYSE:PSA) has declined 14.14% since February 22, 2017 and is downtrending. It has underperformed by 30.84% the S&P500.

Analysts expect Minerva Neurosciences, Inc. (NASDAQ:NERV) to report $-0.43 EPS on March, 12.They anticipate $0.16 EPS change or 59.26% from last quarter’s $-0.27 EPS. After having $-0.28 EPS previously, Minerva Neurosciences, Inc.’s analysts see 53.57% EPS growth. The stock increased 2.42% or $0.12 during the last trading session, reaching $5.3. About 109,085 shares traded. Minerva Neurosciences, Inc. (NASDAQ:NERV) has risen 56.56% since February 22, 2017 and is uptrending. It has outperformed by 39.86% the S&P500.

Among 17 analysts covering Public Storage (NYSE:PSA), 2 have Buy rating, 6 Sell and 9 Hold. Therefore 12% are positive. Public Storage had 62 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Equalweight” rating on Tuesday, July 19 by Barclays Capital. Zacks downgraded Public Storage (NYSE:PSA) on Monday, August 24 to “Buy” rating. Raymond James upgraded the stock to “Outperform” rating in Friday, September 4 report. Jefferies maintained Public Storage (NYSE:PSA) rating on Friday, August 18. Jefferies has “Hold” rating and $210 target. The firm earned “Buy” rating on Wednesday, September 2 by Zacks. As per Monday, November 9, the company rating was maintained by RBC Capital Markets. Robert W. Baird maintained Public Storage (NYSE:PSA) rating on Monday, October 16. Robert W. Baird has “Hold” rating and $205.0 target. Jefferies maintained the stock with “Hold” rating in Monday, November 27 report. The rating was maintained by Argus Research with “Buy” on Wednesday, January 27. Jefferies maintained the shares of PSA in report on Monday, July 24 with “Hold” rating.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company has market cap of $205.11 million. The company's lead product candidate includes MIN-101, a compound for the treatment of patients with schizophrenia that completed Phase IIb clinical trial. It currently has negative earnings. It also offers MIN-202, which completed Phase IIa clinical trial for treating primary insomnia, as well as completed Phase 1b used for the treatment of major depressive disorder; and MIN-117, a compound that completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder.

Among 3 analysts covering Minerva Neurosciences (NASDAQ:NERV), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Minerva Neurosciences had 5 analyst reports since March 9, 2016 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, May 12 by Jefferies. Citigroup initiated the shares of NERV in report on Friday, September 1 with “Buy” rating. JMP Securities maintained the stock with “Market Outperform” rating in Wednesday, March 9 report. The rating was maintained by Jefferies with “Buy” on Thursday, June 22. The firm earned “Buy” rating on Friday, May 27 by Jefferies.

Leave a Reply

Your email address will not be published. Required fields are marked *